Genentech, Myeloid's Approaches To mRNA Technologies

During our Cell & Gene Live, mRNA For Cancer Immunotherapy 2024 Outlook, expert panelists J. Andrew Case (Andy), Head of Supply Chain Cell and Gene Therapies, Genentech/Roche and Daniel Getts, CEO & Co-Founder, Myeloid Therapeutics, provided a brief overview of the different approaches being used to leverage mRNA technology in the CGT space. Getts explained how Myeloid uses mRNA to program cells as an alternative pathway to manufacturing a CAR therapy. Andy shared information about Genentech’s joint venture with BioNTech that’s focused on autologous mRNA cancer vaccines.